At the disease level, whether type 2 diabetes independently increases VTE risk remains debated, as associations often attenuate after adjustment for adiposity and related factors, suggesting residual confounding in observational data [1, 27,28,29,30]
Access depends on health history, goals, and clinical appropriateness
Ozempic can often be taken without insulin and is often prescribed as a standalone treatment for managing type 2 diabetes
Through this connection, TB4 has been studied for its potential to support cell regeneration, promote healthy blood-vessel development, and modulate inflammatory responses
While previously not licensed for younger patients, Saxenda is now approved in the UK for adolescents aged 12 to less than 18 years with a body weight above 60 kg and obesity (BMI corresponding to 30 kg/m for adults), under specific criteria
The clinical evidence is extensive